ziltivekimab   Click here for help

GtoPdb Ligand ID: 11552

Synonyms: COR-001 | COR001 | MEDI-5117 | MEDI5117 | ZILTI
Compound class: Antibody
Comment: Ziltivekimab (MEDI5117) is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signalling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis [2], and it has also been explored for anti-tumour activity [4]. The Fc domain of ziltivekimab has been engineered to extend its half-life (by increasing affinity for FcRn), to support once-monthly administration [1].
Click here for help
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Fc fragment of IgG receptor and transporter Hs Antibody Binding 6.7 pKd - 1
pKd 6.7 (Kd 2.26x10-7 M) [1]
Fc fragment of IgG receptor and transporter Monkey Antibody Binding 6.4 pKd - 1
pKd 6.4 (Kd 3.65x10-7 M) [1]
Description: Binding affinity for cynomolgus monkey FcRn
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-6 Hs Antibody Binding >11.0 pKd - 1
pKd >11.0 (Kd <1x10-11 M) [1]
Description: Binding affinity for the CAT6001 parent of MEDI5117- both share the same anti-IL-6 binding domain. Binding in the SPR assay reached the limit of the assay's sensitivity.